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Abstract: Chronic arsenic exposure results in higher risk of skin, lung, and bladder cancer, 
as well as cardiovascular disease and diabetes. The purpose of this study was to investigate 
the effects on expression of selected genes in the blood lymphocytes from 159 people 
exposed chronically to arsenic in their drinking water using a novel RT-PCR TaqMan  
low-density array (TLDA). We found that expression of tumor necrosis factor-α (TNF-α), 
which activates both inflammation and NF-κB-dependent survival pathways, was strongly 
associated with water and urinary arsenic levels. Expression of KCNA5, which encodes a 
potassium ion channel protein, was positively associated with water and toe nail arsenic 
levels.  Expression  of  2  and  11  genes  were  positively  associated  with  nail  and  urinary 
arsenic, respectively. Because arsenic exposure has been reported to be associated with 
long QT intervals and vascular disease in humans, we also used this TLDA for analysis of 
gene expression in human cardiomyocytes exposed to arsenic in vitro. Expression of the 
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ion-channel genes CACNA1, KCNH2, KCNQ1 and KCNE1 were down-regulated by 1-M 
arsenic. Alteration of some common pathways, including those involved in oxidative stress, 
inflammatory signaling, and ion-channel function, may underlay the seemingly disparate 
array of arsenic-associated diseases, such as cancer, cardiovascular disease, and diabetes.  
Keywords: arsenic; drinking water; low-density array; real-time PCR; cardiomycocytes 
 
1. Introduction 
Extensive epidemiological studies have demonstrated that environmental exposure to arsenic causes 
cancer of the skin, lung, and bladder [1-3] and is also a co-carcinogen in combination with UV light 
for skin cancer [4]. In addition, exposure to arsenic either chronically through the drinking water [5] or 
acutely through medical therapy for acute promyelocytic leukemia or poisoning [6,7] is associated 
with cardiovascular abnormalities [8,9]. This is frequently manifest as a prolongation of the QT (time 
between  initial  deflection  of  QRS  complex  to  the  end  of  T  wave)  interval  as  measured  on  an 
electrocardiogram, resulting in life-threatening malignant ventricular arrhythmias [7]. 
Mechanistic  studies  indicate  that  arsenic  enhances  inflammation  of  vascular  tissues,  activates 
oxidative signaling, disrupts lipid metabolism, and increases lipid oxidation [8]. These effects can 
produce endothelial cell dysfunction directly to the vascular cells and indirectly through the liver. In 
addition, the epigenetic changes induced by arsenic in the liver appear to produce a chronic state of 
stress and inflammation, resulting in not only liver disease but also systemic vascular disease [8]. In 
particular, arsenic exposure increases the risk of prolonged QT interval duration, which is associated 
with atherosclerosis [10,11]. No studies have implicated a role for arsenic on cardiomyocytes per se; 
however, to our knowledge, no in vitro exposures of such cells to arsenic have been performed. 
To understand these diverse effects of arsenic, toxicogenomic analyses involving cDNA microarray 
have been used to identify alterations in global gene expression and pathways in cells exposed to 
arsenic in vitro as well as in animals and humans exposed to arsenic [12-16]. The aberrantly expressed 
genes identified in these studies include those coding for heat shock proteins, DNA damage response, 
antioxidant activity, inflammation signaling, cell-cycle regulation, and apoptosis [16]. 
Although  global  gene  expression  studies  have  provided  considerable  insights  into  the  
toxicity  pathways  affected  by  arsenic,  real-time  PCR  (RT-PCR)  has  been  used  to  confirm  the  
arsenic-associated altered gene expression of only a few genes in these studies. The development of a 
novel  qRT-PCR-based  technique  called  Taqman  Low-Density  Array  (TLDA)  allows  for  the 
simultaneous testing of 48 or 96 genes in a micro-fluidic card format in which the user can specify the 
genes to be analyzed [17]. This technology has been shown to be a sensitive and reproducible system 
for analyzing gene expression [18], and it could be of value in confirming the ability of arsenic to alter 
the expression of genes identified initially by cDNA microarray. 
To explore this possibility, and especially to assess some of the toxicogenomic effects of arsenic 
associated with cardiovascular abnormalities, we used a TLDA to evaluate gene expression in 48 genes 
in RNA isolated from (a) blood of 159 subjects exposed chronically to arsenic as well as (b) human 
cardiomyocytes  exposed  in  vitro  to  arsenic.  The  48  genes  (Table  1)  were  selected  based  on  the Int. J. Environ. Res. Public Health 2011, 8                 
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previous cDNA microarray studies described above and fell into 10 functional groups: endogenous 
control, Nrf2 pathway, heat shock protein, apoptosis, inflammation, NF-κB pathway, cell proliferation 
DNA methylation, DNA repair, and ion channel.  
Table 1. Genes analyzed by TLDA. 
Gene symbol and assay ID  Functional group  Gene description 
ACTB-Hs00242273_m1  Endogenous control  beta actin 
18S-Hs99999901_s1    18S Ribosomal RNA 
HMOX1-Hs00157965_m1  Nrf2 pathway   
KEAP1-Hs00202227_m1    kelch-like ECH-associated protein 1 
MAF-Hs00193519_m1     
MT1A-Hs00831826_s1     
NQO1-Hs00168547_m1     
HSPA1A-Hs00359163_s1  Heat shock protein   
HSP90AA1-Hs00743767_sH     
BAX-Hs00180269_m1  Apoptosis   
BCL2-Hs00153350_m1     
IL1B-Hs00174097_m1  Inflammation   
IL2-Hs00174114_m1     
IL6-Hs00174131_m1     
TNF-Hs00174128_m1     
CHUK-Hs00175141_m1  NF-κB pathway   
NFE2L2-Hs00232352_m1    nuclear factor (erythroid-derived 2)-like 2 
NFKB1-Hs00231653_m1    nuclear factor in B-cells 1 (p105) 
NFKB2-Hs00174517_m1    nuclear factor in B-cells 2 (p49/p100) 
RELB-Hs00232399_m1     
RELA-Hs00153294_m1     
CDKN1A-Hs00355782_m1  Cell proliferation   
CCND1-Hs00277039_m1     
ESR1-Hs00174860_m1     
FOS-Hs00170630_m1     
JUN-Hs99999141_s1     
MYC-Hs00153408_m1     
MSH2-Hs00179887_m1     
NRAS-Hs00180035_m1     
TERT-Hs00162669_m1     
DNMT1-Hs00154749_m1  DNA methylation  DNA (cytosine-5-)-methyltransferase 1 
DNMT3A-Hs00173377_m1     
ERCC1-Hs00157415_m1  DNA repair    
MGMT-Hs00172470_m1     
NTHL1-Hs00267385_m1     
OGG1-Hs00213454_m1     
POLB-Hs00160263_m1     
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Table 1. Cont. 
Gene symbol and assay ID  Functional group  Gene description 
DNMT1-Hs00154749_m1  DNA methylation  DNA (cytosine-5-)-methyltransferase 1 
RAD50-Hs00194871_m1     
TP53-Hs00153349_m1     
CACNA1C-Hs00167681_m1  Ion channel  calcium channel, voltage-dependent, L type, alpha 1C subunit 
SCN5A-Hs00165693_m1    sodium channel, voltage-gated, type V, alpha (long QT 
syndrome 3) 
KCNJ2-Hs00265315_m1    potassium inwardly-rectifying channel, subfamily J, member 2 
KCNA5-Hs00266898_s1    potassium voltage-gated channel, shaker-related subfamily, 
member 5 
KCND3-Hs00542597_m1    potassium voltage-gated channel, Shal-related subfamily, 
member 3 
KCNE1-Hs00264799_s1    potassium voltage-gated channel, Isk-related family, member 1 
KCNQ1-Hs00165003_m1    potassium voltage-gated channel, KQT-like subfamily, 
member 1 
KCNH2-Hs00165120_m1    potassium voltage-gated channel, subfamily H (eag-related), 
member 2 
KCNE2-Hs00270822_s1    potassium voltage-gated channel, Isk-related family, member 2 
This array was used to evaluate gene expression in an arsenic-treated human cardiomyocyte cell 
line (AC16) and in blood from subjects living in Bayingorman (Ba Men) Inner Mongolia, China. This 
population has been exposed to a wide range of arsenic levels (from non-detectable to 1.8 mg/L), 
mainly via drinking water from contaminated artesian wells for more than 20 years [19]. Seafood 
consumption is not common in this population, and arsenic-containing pesticides have not been used in 
Ba  Men  [20].  In  Ba  Men,  more  than  300,000  people  have  been  chronically  exposed  to  arsenic, 
especially in three counties: Hangjin Hou, Lin He and Wu Yuan. Arsenic-associated health effects in 
this population include cancer, dermal, neurological, cardiovascular, and peripheral vascular diseases 
[9,19]. More than 80 percent of the families owned individual wells, making it possible to assess the 
arsenic exposure at the individual level. 
We assessed arsenic levels in the water from each household well and also in toenails and urine of 
each subject. This exposure assessment permitted us to associate gene expression in the blood of the 
subjects to each measure of exposure. In addition, we compared the results in the blood to those 
determined in  cardiomyocytes  exposed  to  arsenic  in  vitro.  This  provided  an  opportunity  to see  if 
arsenic might have a direct effect on such cells, resulting in changes in gene expression found in blood 
and/or consistent with the cardiovascular myopathies associated with arsenic exposure. 
2. Experimental Section 
2.1. Study Subjects 
The study subjects included a total of 159 non-smoking Ba Men residents from the sub-villages of 
Wulan,  Jianshe,  Fengchan,  and  Xinyao  located  in  Sha  Hai  Village,  Hangjn  Hou  County  and  the  
sub-villages of Miaohao and Xigelian located in Sheng Feng Village, Wu Yuan County. Int. J. Environ. Res. Public Health 2011, 8                 
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Questionnaires were administered to all participants to obtain demographic information, arsenic 
exposure, diet, smoking, occupation, pesticide use, and medical information. This study was conducted 
according to the recommendations of the World Medical Association Declaration of Helsinki [21] for 
international health research. All subjects gave written informed consent to participate in this study. 
The research protocol met the requirements for protection of human subject certification by the U.S. 
Environmental Protection Agency.  
2.2. Water Collection and Analysis 
Samples of drinking water from wells were collected from all subjects’ homes in acid-washed tubes, 
transported to the U.S. on blue ice, and analyzed for total arsenic using inductively coupled plasma 
mass spectrometry (ICPMS) as described previously [22]. The detection limit by ICPMS was 0.1 µ g  
of As
III/L. 
2.3. Toenail and Urine Collection and Analysis 
Toenail samples were collected from the study subjects and analyzed as described previously [23]. 
The nail samples were first cleaned by sonication in HPLC-grade water, then acetone was added to 
remove  the  organic  contaminants  from  the  nail  surface.  Nail  samples  were  analyzed  for  arsenic 
concentration by instrumental neutron activation analysis (INAA) at the Nuclear Services Department, 
North Carolina State University, Raleigh, NC, USA [24]. The detection limit by INAA was 0.012 µ g 
of As
III/g. Urine sample collection and analysis were the same as those described by [25]. Briefly, 
morning urine samples were collected from participants on three consecutive days and shipped on dry 
ice  to  the  University  of  Alberta,  Edmonton,  AB,  Canada  for  analysis.  Inductively  coupled  mass 
spectrometry methods were used to measure urinary arsenic, with a detection limit of 0.5 μg of As
III/L. 
2.4. Blood Collection, RNA Isolation, and cDNA Synthesis 
Blood samples were collected in PAXgene blood RNA tubes (Qiagen, Valencia, CA, USA) and 
then stored at –40 °C . The blood samples were transported to the U.S. A via air on blue ice and stored 
at –80 °C  until RNA isolation. Total RNA was isolated using a PAXgene blood RNA kit according to 
the manufacturer’s instructions. RNA was further subjected to DNase I treatment using the Turbo  
DNA-free Kit following manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). 
RNA quality was assessed by analysis with Agilent Bioanalyer 2100 Nono chip. 
2.5. cDNA Synthesis 
Total RNA was reverse-transcribed to cDNA by using High-Capacity cDNA Reverse Transcription 
Kits  (Applied  Biosystems,  CA,  USA).  The  reaction  mix  was  consisted  of  2.5  U/µL  of  reverse 
transcriptase, 1.0 U/µL of RNase inhibitor, 0.4-mM dNTP, 0.2-µ M random primers, and 2 µ g RNA in 
50 µ L total volume. The reaction mixture was incubated at 25 ° C for 10 min and then at 37 °C  for  
120 min. Finally, the mixture was heated at 85 °C  for 5 s. 
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2.6. TaqMan Low-Density Array 
To identify altered gene expression in blood cells, we used a TLDA to examine the expression of  
46 human genes. The 46 genes we selected occurred in several functional groupings (Table 1) that 
represented proposed mode-of-actions of arsenic based on human epidemiology, as well as animal and 
in vitro studies. For the present study, the TaqMan low-density array card was configured in to eight 
identical 48 genes set (duplicate per assay). Each set of genes contained two endogenous control genes, 
β-actin and 18s RNA. The cDNA (5 μL) was mixed with 45 µL of H2O and 50 µL of 2X TaqMan 
Universal PCR Mix (Applied Biosystems, Foster City, CA). Each sample (100 µ L) was loaded into a 
port of the micro-fluid card and run on an ABI 7900HT System (ABI, CA) for 2 min at 50 °C , 10 min 
at 95 °C , followed by 40 cycles for 15 s at 97 ° C and 1 min at 60 °C . 
2.7. In Vitro Studies 
The human cardiomyocyte cell line (AC16) was provided by one of us (M. Davidson) and were 
cultured in Dulbecco’s Modified Eagle’s/F12 medium supplemented with 12.5% fetal bovine serum 
(Invitrogen, Carlsbad, CA, USA), penicillin (100 U/mL), and streptomycin (100 µ g/mL) and maintained 
at 37 ° C in 95% air and 5% CO2. The MTT cell-proliferation assay kit (Roche, Indianapolis, IN, USA) 
was used to assess cell viability. Briefly, 1X 10
4 AC16 cells were seeded in 96-well plates in 0.2 mL of 
medium. After 24 h of incubation, sodium arsenite was added to the cultures at final concentrations of 
0.1  to  5.0  µ M,  and  cells  were  incubated  for 3  days.  Cell  viability was  measured  at  560  nm  and 
expressed as a percentage of controls. The assay was conducted in triplicate wells for each treatment, 
and a total of 3 experiments were conducted for all samples. 
2.8. Arsenite Treatment and RNA Isolation 
After incubating the seeded cells for 24 h, the cells were treated with sodium arsenite (Sigma,  
St. Louis, MO, USA) at concentrations of 0 to 2.5 μM for 72 h. Total RNA was isolated from the 
control and the arsenite-treated cells using the RNeasy RNA Isolation Kit (Qiagen, CA, USA). cDNA 
synthesis and the TILDA were conducted as described above; each sample was tested in duplicate.  
2.9. Data Analysis 
The TLDA data were analyzed by SDS vers 2.2.2 software (ABI). Threshold cycle (Ct) data for all 
target genes and control gene 18s RNA were used to calculate ∆Ct values [∆Ct = Ct (target gene) –  
Ct (18s RNA)]. Then, ∆∆Ct values were calculated by subtracting the calibrator (control) from the ∆Ct 
values of each target. Multiple linear regression models were used to evaluate the relationship between 
gene expression (∆Ct) and nail, water, and urine arsenic levels. Because arsenic measures were highly 
right-skewed,  they  were  log10-transformed  prior  to  analysis.  The  dependent  variable  was  gene 
expression as measured by ∆Ct value, and the independent variable of interest was the log-transformed 
arsenic measure. Log transformation did not improve the skew of ∆Ct measures, which tended to be 
fairly symmetric. 
Three types of models were constructed: an unadjusted model; a model that included variables to 
adjust for age and sex; and a model adjusting for age, body mass index, sex, alcohol use, pesticide Int. J. Environ. Res. Public Health 2011, 8                 
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exposure in the past five years, and education level. Because adjusting for factors other than age and 
sex did little to change the relationship between arsenic density and gene expression, results adjusting 
for age and sex were reported. Slope coefficients shown in Table 3 can be interpreted as the change in 
gene expression (∆Ct) associated with a 1-log10 increase in the water, urine, or nail arsenic levels.  
Non-linearity  in  the  relationship  between  arsenic  and  gene  expression  was  evaluated  by  fitting  a  
two-degree  fractional  polynomial  model  and  comparing  it  with  a  linear  model  using  a  deviance 
difference test [26]. Statistical analyses were conducted using Stata SE version 10.1 (Stata Corporation, 
College Station, TX, USA, 2008).  
3. Results  
3.1. Study Subjects 
Demographic information and pesticide use related to the study subjects are shown in Table 2. All 
subjects were non-smokers. Most (79%) of the 159 study subjects, including 48 males and 111 females, 
were  farmers.  The  nail  arsenic  concentrations  ranged  from  0.24  to  63.14  μg/g.  Water  arsenic 
concentrations ranged from non-detectable to 826 mg/L. The average years of arsenic exposure for the 
study subjects was 13 ±  6 (SD) years.  
Table 2. Selected characteristics of study population. 
Variables  Number of subjects  Percent 
Gender     
Male  48  30.2 
Female  111  69.8 
Age     
11–18  49  30.8 
19–49  93  58.5 
>50  17  10.7 
Occupation     
Farmer  110  69.6 
Other  48  30.4 
Education     
None  24  15.2 
Elementary  50  31.6 
Jr high school  76  48.1 
High school  8  5.1 
Meat frequency     
Often  159  100 
Vegetable frequency     
Occasionally  1  0.6 
Often  158  99.4 
Use of pesticides in past 5 years     
Yes  45  28.3 
No  114  71.7 
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Table 2. Cont. 
Variables  Number of subjects  Percent 
Alcohol use 2 x/week     
No  114  95.6 
Yes  7  4.4 
Eat fish frequency     
Never  1  0.6 
Occasionally  146  91.8 
Often  12  7.5 
3.2. Variability of Gene Expression Data from TLDA 
To assess the reproducibility of the TILDA, sixteen samples of cDNAs from human blood were run 
repeatedly. ΔCt (The Ct values normalized to loading control) for experiment 1 were plotted against 
ΔCt  for  repeated  TLDA  experiments.  The  data  showed  a  small  variation  with  high  correlation 
coefficients (0.985 and 0.971) (Figures 1A,B). The data showed that the ΔCts were reproducible. 
Figure 1. Viability of cardiomyocytes exposed to sodium arsenite. AC16 cells were seeded 
in a 96-well plate and exposed for three days to various concentrations of sodium arsenite. 
Cell viability was determined by the MTT assay. Data shown are mean ±  SD from three 
independent experiments. 
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3.3. Arsenic-Altered Gene Expression in the Blood 
The TLDA showed that the majority of selected genes were expressed in the blood, most of them 
with Cts < 30. However, hTERT and CANC1 were under the detectable limit (Ct > 37) and, thus, were 
excluded from further analysis. A linear regression was employed to determine the significance of 
association  of  expression  with  water  arsenic  levels.  The  data  from  KCNA5  and  TNFα  expression 
showed a positive association with water arsenic exposure (Table 3). Furthermore, the expression level 
of KCNA5 was also associated with nail arsenic concentrations, whereas that of TNF-α was also 
associated with urine arsenic concentrations.  
In addition to KCNA5 and TNF-, the altered expressions of nine other genes were associated with 
urinary  arsenic  concentrations  (Table  3).  The  associated  molecular  functions  for  these  11  gene 
products included stress response, inflammation, apoptosis, DNA methylation, DNA repair, and the 
NF-B signal transduction pathway. TNF- is the prototypic pro-inflammatory cytokine and master 
regulator of cell apoptosis, inflammation, and tumorigenesis. TNF- is an important constituent of the 
NF-kB signal  pathway. There was no evidence  of a  significant (p  < 0.05)  non-linear relationship 
between water, nail, or urine arsenic levels and gene expression, and in all cases a 2-degree fractional 
polynomial model was not an improvement over a linear regression model. 
Table 3. Association of gene expression with water, nail, or urine arsenic levels 
a. 
Gene  Function group  Water arsenic  Nail arsenic  Urine arsenic 
    Slope  p value 
b  Slope  p value  Slope  p value 
KCNA5  Ion channel  0.343  0.031  0.547  0.043  0.189  0.078 
TNF-  Inflammation  0.178  0.043      0.146  0.013 
POLB  DNA repair      0.306  0.049  0.135  0.028 
MAF  Nrf2 pathway          0.137  0.038 
BCL2  Apoptosis          0.131  0.033 
BAX  Apoptosis          0.117  0.038 
DNMT1  DNA methylation          0.122  0.031 
HSP1  Heat shock protein          0.105  0.054 
JUN  Signal transduction          0.149  0.023 
NTHL1  DNA repair          0.132  0.034 
RAD50  DNA repair          0.113  0.050 
a Only those slopes and p-values with significant association with arsenic (p < 0.05) are shown;  
b N = 159, p-values were age and sex adjusted. 
3.4. Cardiomyocytes Treated with Arsenite In Vitro 
Results  from  the  MTT  assay  showed  that  the  viability  of  AC16  cells  after  arsenic  treatment 
decreased as arsenite concentrations increased (Figure 2). For the mRNA levels of 46 genes, three 
different patterns of response were observed. The expression of one group of genes was increased at 
low  concentrations  of  arsenic  (0.5  and  1  µ M)  but  decreased  at  higher  concentrations  (>2.5  M, 
Figure 3A). These included the genes associated with heat shock proteins, inflammatory molecules, 
apoptosis, DNA repair, and the NFkB pathways (Figure 3A). A second group, including the genes 
HMOX1, NQO1 and ESR1, showed increased expression relative to increased arsenic concentrations Int. J. Environ. Res. Public Health 2011, 8                 
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up to 5 M (Figure 3B). A third group showed down-regulated gene expression relative to arsenic 
concentration, and these included the ion channel genes CACNA1C, KCNE1, KCNQ1 and SCDA5; the 
DNA repair genes ERCC1 and NTHL1; and the cytokine gene IL6 (Figure 3C). 
Figure 2. Correlation plot of mean ∆Ct values from repeated TLDA experiments. Panels A 
and  B  show  representative  Ct  values  obtained  from  repeated  experiment  with  two 
different samples. The ΔCt (The Ct values normalized to loading control) for experiment 1 
was plotted against the ΔCt for repeated TILDA runs. Linear regression analysis was used 
to determined Pearson correlation coefficient (r) and p values. 
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Values in Figure 3 are fold changes of expression in treated cells relative to control cells. The Ct 
values of untreated cells were designated as calibrators. The relative quantity (RQ) was calculated by 
the  equation  RQ  =  2
–Ct.  (A)  Up-regulated  gene  expression  at  low  concentrations  of  arsenic  but  
down-regulated expression at high concentrations (2.5 M). (B) Up-regulated gene expression relative 
to increasing concentrations of arsenic. (C) Down-regulated gene expression relative to increasing 
concentrations of arsenic. 
4. Discussion 
4.1. Changes in Gene Expression in Blood Associated with Chronic Arsenic Exposure 
In this study, we investigated the molecular responses to arsenic exposure in humans and cultured 
cardiomyocytes using a novel TLDA in order to better understand the mode of action of arsenic. In 
blood, we found that alterations in expression of 11 genes, especially those associated with stress 
response,  DNA  repair,  DNA  methylation,  the  NF-κB  signaling  pathway,  and  iron  channels,  were 
positively  associated  with  arsenic  exposure.  Urinary  arsenic  concentrations  were  associated  with 
altered expression of 10 genes, 8 of which were associated only with urinary arsenic levels. Expression 
of 3 genes was associated with binary combinations of the 3 exposure assessments (Table 3). Based on 
the TLDA we designed, urinary arsenic was the most robust measure of exposure. Considering all the Int. J. Environ. Res. Public Health 2011, 8                 
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exposure estimates, expression of TNF-α was associated with both water and urinary concentrations of 
arsenic, that of POLB was associated with nail and urinary levels, and that of KCNA5 was associated 
with  water  and  nail  levels  (and  was  borderline  significant  with  urinary  arsenic).  Because  altered 
expression of these genes was associated with 2 of the 3 exposure assessments, we view that arsenic 
exposure clearly played a role in the altered expression of KCNA5, TNF-α, and POLB as assessed by 
the TLDA in this study.  
Figure  3.  Gene  expression  analysis  of  cardiomyocyte  AC16  cells  exposed  to  sodium 
arsenite for 72 h as determined by a TLDA. 
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Figure 3. Cont. 
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Our finding that altered gene expression was associated most frequently with urinary arsenic levels 
is interesting in light of the finding that urinary arsenic levels were a stronger predictor of skin lesions 
than arsenic levels in drinking water [27,28]. In addition, chromosomal aberrations have been shown to 
be associated with urinary arsenic [29]. Urinary arsenic receives input from external sources and tissue 
storage  and  likely  reflects  the  body  burden  of  arsenic.  Consequently,  altered  gene  expression 
associated with urinary arsenic may reflect current arsenic exposure levels. 
Expression of KCNA5 influences various cell functions, such as cell migration, proliferation and 
apoptosis.  Over-expression  of  human  KCNA5  in  pulmonary  artery  smooth  muscle  cells  induced 
membrane hyperpolarization and increased cell apoptosis [30]. Down-regulation of KCNA5 expression 
by an antisense oligonucleotide resulted in membrane depolarization [31]. KCNA5 expression occurs 
in response to oxidative stress mediated by the Sp1 transcription factor [32]. 
TNF-α  is  a  cytokine  involved  in  cell  proliferation,  differentiation,  and  apoptosis.  Induction  of  
TNF-α  by  arsenic  exposure  has  been  observed  consistently  both  in  vitro  and  in  vivo  [33,34].  
Over-expression of TNF-α and GM-CSF has been associated with neoplastic transformation in the skin. 
TGF-α transgenic mice exhibited keratinocyte hyper-proliferation and tumors in the epithelium [35]. 
Our PCR array profiling showed that TNF-α expression was positively associated with chronic arsenic 
exposure,  indicating  that  this  inflammation  cytokine  is  involved  in  arsenic  toxicity  and  possibly 
carcinogenesis. Some TNFs may induce both apoptotic and anti-apoptotic pathways, the increased 
expression  of  TNF-,  along  with  BCL2  and  BAX,  strongly  indicate  the  activation  of  the  
anti-apoptotic/NF-B/BCL2 pathway in the subjects exposed to environmental arsenic. 
Expression of JUN and MAF was positively associated with urinary arsenic levels in this study. The 
coordinated induction of these two genes suggests that the Nrf2 pathway plays a crucial role in the 
cellular defense against arsenic-induced oxidative stress, which has been reported to be involved in the 
toxicity induced by low-dose arsenic exposure [36]. The Nrf2 pathway plays an important role by 
mediating an antioxidant response against the adverse effects of excess ROS production generated by Int. J. Environ. Res. Public Health 2011, 8                 
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arsenic metabolites [37]. The transcription factor Nrf2 is a central regulator in the activation of many 
genes  related  to  antioxidant  response,  such  as  glutathione  S-transferase  (GST),  NAD(P)H,  quinine 
reductases (NQO1), heat shock protein, and heme oxygenase 1 (HO-1). Although we did not have 
GGT1  or  NFKBIE  on  our  array,  their  expression  levels  in  lymphoblasts  may  be  biomarkers  of 
susceptibility arsenic toxicity [38]. 
The small Maf basic leucine zipper protein has emerged as a crucial regulator of mammalian gene 
expression.  During  oxidative  stress,  Nrf2  heterodimerizes  with  small  Maf  and  binds  antioxidant 
response  element  (ARE)  sequences,  thereby  transcriptionally  activating  ARE  [37].  The  activator 
protein (AP-1) transcription factor is a protein complex consisting c-Jun and c-Fos, which are involved 
in the regulation of many different kind of cellular processes, including proliferation and survival, 
differentiation, and transformation. Consistent with this is the finding that expression of c-Jun and  
c-Fos was up-regulated in human GM847 fibroblast cells exposed to arsenic [39]. Our finding of  
up-regulated expression of  c-Jun and Maf in humans exposed chronically to arsenic suggests that 
arsenic may alter AP-1 and NF-b activity. The NFB signaling pathway is involved in the immune 
response, inflammation, and apoptosis, and the inflammation/NF-B signaling pathway was reported 
to be activated in infants born to arsenic-exposed mothers [15]. Our data and that of others [15,40] 
suggest  that  NFB  activation  induced  by  arsenic  exposure  may  play  an  important  role  in  arsenic 
toxicity in humans. 
Arsenic exposure is associated with a variety of diseases, including cancer, cardiovascular disease, 
and diabetes [1,8,41]. The mechanisms underlying the carcinogenicity of arsenic are varied; however, 
oxidative  stress  is  a  likely  mode  of  action  for  arsenic  [1,3].  Arsenic  metabolites  generate  ROS, 
resulting in damage to DNA and other macromolecules. For example, ROS-generating metabolites of 
arsenic can induce DNA breaks, resulting in chromosomal mutations [42]. The association of arsenic 
exposure  with  increased  gene  expression  of  nucleotide  excision  repair,  DNA  methylation,  and 
oxidative DNA repair pathways observed in this study is consistent with this mechanism of arsenic 
carcinogenicity.  As  discussed  below,  oxidative  stress  may  also  play  a  role  in  the  cardiovascular 
diseases associated with arsenic exposure, further supporting a role for the genes identified here in 
arsenic-associated disease.  
4.2. Changes in Gene Expression in Arsenic-Exposed Cardiomyocytes  
Several  reviews  have  concluded  that  arsenic  exposure  is  associated  with  cardiovascular  
disease  [8,41,43].  The  specific  diseases  include  carotid  atherosclerosis,  reduced  microcirculation, 
prolonged  QT  interval  and  increased  QT  dispersion,  hypertension,  coronary  artery  disease,  and 
cerebral  infarction.  Epidemiology  studies  support  the  view  that  chronic  arsenic  exposure  is  an 
independent  risk  factor  for  cardiovascular  disease.  Our  previous  work  has  demonstrated  a  clear 
relationship between chronic arsenic exposure and QT interval prolongation [5]. 
The mechanistic basis for this collection of arsenic-associated health effects appears to involve a 
role for oxidative stress and activated immune response pathways, indicating a pro-hyperinflammatory 
condition [8]. In arsenic-exposed mice, the arterial wall is inflamed, and liver sinusoidal endothelium 
differentiates into a continuous endothelium that limits nutrient exchange and waste elimination. Thus, Int. J. Environ. Res. Public Health 2011, 8                 
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current models focus on altered signaling by arsenic, resulting in inflammation  of liver and heart 
arteries [8]. 
To our knowledge, our study is the first to expose heart cells (cardiomyocytes) to arsenic in vitro. 
We found that 25 of the 46 genes assessed by our TLDA exhibited altered expression after exposure of 
cardiomyocytes to arsenic (Figure 3). Most interesting was that these affected genes fell into three 
categories:  (1)  those  whose  expression  was  up-regulated  at  low  concentrations  of  arsenic  but  
down-regulated  at  high  concentrations  of  arsenic  (Figure  3A),  those  whose  expression  was  
up-regulated with increasing concentrations of arsenic (Figure 3B), and those whose expression were 
down-regulated with increasing concentrations of arsenic (Figure 3C). 
Various studies have noted consistently that, for some genes, arsenic induces expression at low 
doses  but  reduces  expression  at  high  doses  in  vitro  and  in  vivo.  In  human  keratinocytes,  sodium 
arsenite induced apurinic/apyrimidinic endonuclease, DNA polymerase β, DNA ligase, and telomerase 
up to 1 µ M, but down-regulated these genes at concentration >1 µ M [39,44,45]. The sub-micromolar 
concentrations of sodium arsenite used in our study are similar to the levels of arsenic found in the 
blood of subjects exposed chronically to arsenic in Inner Mongolia [46]. These results suggest that low 
doses of arsenic trigger an adaptive response that alleviates the adverse effects of arsenic cytotoxicity 
and  oxidative  stress.  Some  of  this  response  could  protect  against  cancer  by  elevated  DNA  repair 
capacity.  Other  responses,  such  as  increased  cell  proliferation,  or  inhibited  apoptosis,  may  be 
cytoprotective, but could also be procarcinogenic by allowing mutant cells to survive. 
Transcriptional regulation plays a key role in the regulation of potassium channel genes involved in 
cardiac muscle function and accounts for some of the variation of the elecrtro-physiological phenotype 
of  myocytes  [47].  Therefore,  expression  of  KCNA5  may  have  been  altered  by  arsenic  in  the 
cardiomyocytes, but because of the low levels of this mRNA in our cells, we could not confirm such a 
change.  However,  we  observed  transcriptional  changes  for  several  iron-channel  genes,  including 
KCNE1, KCNH2, and CADA1C in cardiomyocytes treated with arsenite. Alterations in such genes 
could play a role in the cardiac arrhythmias associated with arsenic exposure [5,48]. 
As  noted  earlier,  epidemiological  studies  have  identified  arsenic  exposure  as  a  causative  agent  
for diabetes [5,41,43]. Although we did not design our TLDA to assess genes potentially involved in 
arsenic-associated  diabetes,  recent  studies  [49,50]  suggest  that  the  arsenic-associated  decrease  in 
insulin secretion found in rodent models may be partially responsible for the altered cell division and 
proliferation associated with arsenic exposure. In vitro studies found that free Ca
(2+) oscillations needed 
for  glucose-stimulated  insulin  secretion  were  abated  in  the  presence  of  subchronic,  low  arsenite 
concentrations [50]. Thus, it is interesting that we found that arsenic reduced expression of a variety of 
ion channel genes, including the calcium channel, voltage-dependent, L type alpha 1C subunit gene 
CACNA1C in cardiomyocytes (Figure 3C). Although it is difficult to make firm conclusions and direct 
comparisons of gene expression in cardiomyocytes and blood due to the nature of the study design and 
differences in absorption and metabolismwe found that five genes showed altered expression both in 
blood and in the treated cardiomyocytes: BAX, DNMT1, JUN, NTHL1, and RAD50. 
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5. Conclusions  
In  conclusion,  this  study  shows  that  the  TLDA  is  a  sensitive  and  reproducible  technique  for 
quantifying expression of multiple genes. Our finding in the blood of arsenic-exposed subjects of the 
simultaneous increase in gene expression involved in antioxidant response, inflammatory response, 
DNA repair, apoptosis, DNA methylation, and iron channels, suggests an integrative mode of action of 
arsenic in humans. Oxidative stress, inflammatory response, and altered ion-channel function may 
underlay aspects of the cancer, cardiovascular disease, and diabetes associated with chronic arsenic 
exposure.  A recent  study has  also identified the  importance of epigenetic changes in  people with 
arsenicosis [51]. Further studies involving specific cell types are needed to identify the complete set of 
pathways affected by arsenic that result in the array of seemingly unrelated diseases.  
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